scholarly journals Prevalence of occult adrenal insufficiency and the prognostic value of a short corticotropin stimulation test in patients with septic shock

2009 ◽  
Vol 13 (2) ◽  
pp. 85-91 ◽  
Author(s):  
Muzaffar Maqbool ◽  
Zafar Amin Shah ◽  
Fayaz Ahmad Wani ◽  
Abdul Wahid ◽  
Shaheena Parveen ◽  
...  
2006 ◽  
Vol 103 (4) ◽  
pp. 1057
Author(s):  
Pekka Loisa ◽  
Ari Uusaro ◽  
Esko Ruokonen

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A99-A99
Author(s):  
Margret J Einarsdottir ◽  
Maria Bankvall ◽  
Jairo Robledo-Sierra ◽  
Per-Olof Rödström ◽  
Penelope Trimpou ◽  
...  

Abstract Objective: Glucocorticoid (GC) treatment suppress the hypothalamic-pituitary-adrenal axis, which may lead to tertiary adrenal insufficiency. This study aimed to investigate the prevalence of tertiary adrenal insufficiency among patients with oral lichen planus treated with topical GC (clobetasol propionate) in the oral cavity, a standard treatment option for this condition. Methods: In this cross-sectional study, we included 24 patients with oral lichen planus receiving long-term (> 6 weeks) clobetasol propionate treatment. Adrenal function was assessed by measuring serum cortisol between 8–9 AM, after a withdrawal of treatment for 48 hours. For patients with serum cortisol concentrations below 280 nmol/L (10 µg/dL), a 250 µg corticotropin stimulation test was performed. Results: Twenty patients had normal serum cortisol concentrations (range 280–621 nmol/L), whereas four patients had low serum cortisol concentrations (13, 45, 63, and 229 nmol/L, respectively). A corticotropin stimulation test revealed partial adrenal insufficiency in two patients (serum cortisol peak level 350 nmol/L and 360 nmol/L) and severe adrenal insufficiency in another two patients (serum cortisol peak level 150 nmol/L and 210 nmol/L). Conclusion: In this small study, approximately 20% of patients receiving chronic topical GCs treatment for oral lichen planus had tertiary adrenal insufficiency. It is essential to be aware of this potential risk and to inform patients about the need for GC stress-doses during an intercurrent illness episode.


2016 ◽  
Vol 6 (5) ◽  
pp. 154-157
Author(s):  
Ekaterina Manuylova ◽  
Laura M. Calvi ◽  
Catherine Hastings ◽  
G. Edward Vates ◽  
Maryanne Stahlecker-Etter ◽  
...  

2006 ◽  
Vol 103 (4) ◽  
pp. 1056-1057 ◽  
Author(s):  
Ioanna Dimopoulou ◽  
Maria Zervou ◽  
Evangelia Douka ◽  
Callirhoe Augustatou ◽  
Apostolos Armaganidis ◽  
...  

2005 ◽  
Vol 39 (2) ◽  
pp. 335-338 ◽  
Author(s):  
Amy N Bower ◽  
Lance J Oyen

OBJECTIVE: To review dexamethasone interaction with corticotropin stimulation testing, particularly as it applies to treating septic shock. DATA SOURCES: Pertinent literature was identified through MEDLINE (1966–February 2004) using combinations of the key words dexamethasone, adrenocorticotropic hormone stimulation, and pretreat. Only articles written in the English language and evaluating human subjects were considered. Reference lists of identified articles were reviewed for additional citations. DATA SYNTHESIS: Accurate interpretation of the corticotropin stimulation test is important to identify patients with septic shock who may benefit from corticosteroid supplementation. In healthy volunteers, short-term dexamethasone administration prior to the corticotropin stimulation test may depress the baseline cortisol level, but does not inhibit the response to the corticotropin challenge. This may result in a slight increase in the difference between baseline and post-stimulation values. CONCLUSIONS: In 2 small trials in healthy adults, short-term, low-dose dexamethasone pretreatment decreased baseline cortisol levels, but values following corticotropin stimulation were unaffected. Accordingly, caution in interpreting corticotropin stimulation test results is warranted. However, the application of the findings from these studies to patients with septic shock is difficult, given the important differences in physiology between normal and septic patients. As of December 29, 2004, a dexamethasone dose >2 mg or prolonged dexamethasone therapy (>2 days, totaling 4 mg) preceding corticotropin stimulation has not been studied in any population.


2018 ◽  
Author(s):  
Bina Akura ◽  
Jose Batubara ◽  
Zakiudin Munasir ◽  
Gunati unknown ◽  
Joedo Prihartono ◽  
...  

2005 ◽  
Vol 33 (4) ◽  
pp. 855-859 ◽  
Author(s):  
Cristiane F. Pizarro ◽  
Eduardo J. Troster ◽  
Durval Damiani ◽  
Joseph A. Carcillo

Sign in / Sign up

Export Citation Format

Share Document